Caution:  Federal law prohibits dispensing without prescription.

Fluothane (halothane, USP) is supplied as a liquid and is vaporized for use as an inhalation anesthetic. It is 2-bromo-2-chloro-1, 1, 1-trifluoro-ethane and has the following structural formula:


C 2 HBrClF 3

The molecular weight is 197.38. The drug substance halothane molecule has an asymmetric carbon atom; the commercial product is a racemic mixture. Resolution of the mixture has not been reported.*

* Klaus Florey, editor, Analytical Profiles of Drug Substances, Vol. 1, page 127, (1972).

Halothane is miscible with alcohol, chloroform, ether, and other fat solvents.

The specific gravity is 1.872-1.877 at 20°C, and the boiling point (range) is 49°C-51°C at 760 mm Hg. The vapor pressure is 243 mm Hg at 20°C. The blood/gas coefficient is 2.5 at 37°C, and the olive oil/water coefficient is 220 at 37°C. Vapor concentrations within anesthetic range are nonirritating and have a pleasant odor.

Fluothane is nonflammable, and its vapors mixed with oxygen in proportions from 0.5 to 50% (v/v) are not explosive.

Fluothane does not decompose in contact with warm soda lime. When moisture is present, the vapor attacks aluminum, brass, and lead, but not copper. Rubber, some plastics, and similar materials are soluble in Fluothane; such materials will deteriorate rapidly in contact with Fluothane vapor or liquid. Stability of Fluothane is maintained by the addition of 0.01% thymol (w/w), up to 0.00025% ammonia (w/w).

Fluothane is an inhalation anesthetic. Induction and recovery are rapid, and depth of anesthesia can be rapidly altered. Fluothane progressively depresses respiration. There may be tachypnea with reduced tidal volume and alveolar ventilation. Fluothane is not an irritant to the respiratory tract, and no increase in salivary or bronchial secretions ordinarily occurs. Pharyngeal and laryngeal reflexes are rapidly obtunded. It causes bronchodilation. Hypoxia, acidosis, or apnea may develop during deep anesthesia.

Fluothane reduces the blood pressure and frequently decreases the pulse rate. The greater the concentration of the drug, the more evident these changes become. Atropine may reverse the bradycardia. Fluothane does not cause the release of catecholamines from adrenergic stores. Fluothane also causes dilation of the vessels of the skin and skeletal muscles.

Cardiac arrhythmias may occur during Fluothane anesthesia. These include nodal rhythm, AV dissociation, ventricular extrasystoles, and asystole. Fluothane sensitizes the myocardial conduction system to the action of epinephrine and norepinephrine, and the combination may cause serious cardiac arrhythmias. Fluothane increases cerebrospinal-fluid pressure. Fluothane produces moderate muscular relaxation. Muscle relaxants are used as adjuncts in order to maintain lighter levels of anesthesia. Fluothane augments the action of nondepolarizing relaxants and ganglionic-blocking agents. Fluothane is a potent uterine relaxant.

The mechanism(s) whereby Fluothane and other substances induce general anesthesia is unknown. Fluothane is a very potent anesthetic in humans, with a minimum alveolar concentration (MAC) determined to be 0.64%. The MAC has been found to decrease with age (see MAC table in "Dosage and Administration").

Fluothane (halothane, USP) is indicated for the induction and maintenance of general anesthesia.


Fluothane is not recommended for obstetrical anesthesia except when uterine relaxation is required.

When previous exposure to Fluothane was followed by unexplained hepatic dysfunction and/or jaundice, consideration should be given to the use of other agents.



Fluothane should be used in vaporizers that permit a reasonable approximation of output, and preferably of the calibrated type. The vaporizer should be placed out of circuit in closed-circuit rebreathing systems; otherwise, overdosage is difficult to avoid. The patient should be closely observed for signs of overdosage, i.e., depression of blood pressure, pulse rate, and ventilation, particularly during assisted or controlled ventilation.

Fluothane increases cerebrospinal-fluid pressure. Therefore, in patients with markedly raised intracranial pressure, if Fluothane is indicated, administration should be preceded by measures ordinarily used to reduce cerebrospinal-fluid pressure. Ventilation should be carefully assessed, and it may be necessary to assist or control ventilation to ensure adequate oxygenation and carbon dioxide removal.

In susceptible individuals, halothane anesthesia may trigger a skeletal-muscle hypermetabolic state leading to a high oxygen demand and the clinical syndrome known as malignant hyperthermia. The syndrome includes nonspecific features such as muscle rigidity, tachycardia, tachypnea, cyanosis, arrhythmias, and unstable blood pressure. (It should also be noted that many of these nonspecific signs may appear with light anesthesia, acute hypoxia, etc.) An increase in overall metabolism may be reflected in an elevated temperature (which may rise rapidly, early or late in the case, but usually is not the first sign of augmented metabolism) and an increased usage of the CO 2 absorption system (hot canister). PaO 2 and pH may decrease, and hyperkalemia and a base deficit may appear. Treatment includes discontinuance of triggering agents (e.g., halothane), administration of intravenous dantrolene, and application of supportive therapy. Such therapy includes vigorous efforts to restore body temperature to normal, respiratory and circulatory support as indicated, and management of electrolyte-fluid-acid-base derangements. Renal failure may appear later, and urine flow should be sustained if possible. It should be noted that the syndrome of malignant hyperthermia secondary to halothane appears to be rare.


When appropriate, as in some cases where discharge is anticipated soon after general anesthesia, patients should be cautioned not to drive automobiles, operate hazardous machinery, or engage in hazardous sports for 24 hours or more (depending on the total dose of Fluothane, condition of the patient, and consideration given to other drugs administered after anesthesia).


Epinephrine or norepinephrine should be employed cautiously, if at all, during Fluothane (halothane, USP) anesthesia, since their simultaneous use may induce ventricular tachycardia or fibrillation.

Nondepolarizing relaxants and ganglionic-blocking agents should be administered cautiously, since their actions are augmented by Fluothane (halothane, USP).

Clinical experience and animal experiments suggest that pancuronium should be given with caution to patients receiving chronic tricyclic antidepressant therapy who are anesthetized with halothane, because severe ventricular arrhythmias may result from such usage.


An 18-month inhalational carcinogenicity study of halothane at 0.05% in the mouse revealed no evidence of anesthetic-related carcinogenicity. This concentration is equivalent to 24 hours of 1% halothane.

Mutagenesis testing of halothane revealed both positive and negative results. In the rat, one-year exposure to trace concentrations of halothane (1 and 10 ppm) and nitrous oxide produced chromosomal damage to spermatogonia cells and bone marrow cells. Negative mutagenesis tests included: Ames bacterial assay, Chinese hamster lung fibroblast assay, sister chromatid exchange in Chinese hamster ovary cells, and human leukocyte culture assay.

Reproduction studies of halothane (10 ppm) and nitrous oxide in the rat caused decreased fertility. This trace concentration corresponds to 1/1000 the human maintenance dose.


Teratogenic Effects:   Pregnancy Category C. Some studies have shown Fluothane to be teratogenic, embryotoxic, and fetotoxic in the mouse, rat, hamster, and rabbit at subanesthetic and/or anesthetic concentrations. There are no adequate and well-controlled studies in pregnant women. Fluothane should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.


The uterine relaxation obtained with Fluothane, unless carefully controlled, may fail to respond to ergot derivatives and oxytocic posterior pituitary extract.


It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Fluothane is administered to a nursing woman.


Extensive clinical experience reveals that maintenance concentrations of halothane are generally higher in infants and children, and that maintenance requirements decrease with age. See MAC table, based upon age, in "Dosage and Administration."


The following adverse reactions have been reported: mild, moderate, and severe hepatic dysfunction (including hepatic necrosis); cardiac arrest; hypotension; respiratory arrest; cardiac arrhythmias; hyperpyrexia; shivering; nausea; and emesis.


In the event of overdosage, or what may appear to be overdosage, drug administration should be stopped, and assisted or controlled ventilation with pure oxygen initiated.


Fluothane may be administered by the nonrebreathing technique, partial rebreathing, or closed technique. The induction dose varies from patient to patient but is usually within the range of 0.5% to 3%. The maintenance dose varies from 0.5% to 1.5%.

Fluothane may be administered with either oxygen or a mixture of oxygen and nitrous oxide.

Fluothane should not be kept indefinitely in vaporizer bottles not specifically designed for its use. Thymol does not volatilize along with Fluothane and, therefore, accumulates in the vaporizer and may, in time, impart a yellow color to the remaining liquid or to wicks in vaporizers. The development of such discoloration may be used as an indicator that the vaporizer should be drained and cleaned, and the discolored Fluothane (halothane, USP) discarded. Accumulation of thymol may be removed by washing with diethyl ether. After cleaning a wick or vaporizer, make certain all the diethyl ether has been removed before reusing the equipment to avoid introducing ether into the system.

Because of the more rapid uptake of Fluothane and the increased blood concentration required for anesthesia in younger patients, the minimum alveolar concentration (MAC) 1 values will decrease with age as follows:

Age                     MAC %

Infants                    1.08

  3 yrs.                    0.91

10 yrs.                    0.87

15 yrs.                    0.92

24 yrs.                    0.84

42 yrs.                    0.76

81 yrs.                    0.64


Fluothane® (halothane, USP) is available in unit packages of 125 mL (NDC 0046-3125-81) and 250 mL (NDC 0046-3125-82) of halothane, USP, stabilized with 0.01% thymol (w/w) and up to 0.00025% ammonia (w/w).


Store at room temperature (approximately 25°C) in a tight, closed container.

Protect from light.

Use carton to protect contents from light.


  1. Gregory, GA et al: Anesthesiology 1969; 30 ( ):488-491.

Manufactured for:  

Ayerst Laboratories Inc.

A Wyeth-Ayerst Company

Philadelphia, PA 19101

By ICI Chemicals and Polymers Ltd.

Runcorn, Cheshire, U.K.

CI 3816-6 Revised June 23, 1994